- Home
- CTMX
as 03-28-2025 4:00pm EST
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 62.3M | IPO Year: | 2015 |
| Target Price: | $5.77 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $5.85 | Next Earning Date: | 03-06-2025 |
| Revenue: | $138,103,000 | Revenue Growth: | 36.45% |
| Revenue Growth (this year): | -43.67% | Revenue Growth (next year): | -55.85% |
Stock Insider Trading Activity of CytomX Therapeutics Inc. (CTMX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCarthy Sean A. | CTMX | CEO | Mar 18 '25 | Sell | $0.60 | 37,656 | $22,555.94 | 995,195 | |
| ROWLAND LLOYD A | CTMX | General Counsel | Mar 18 '25 | Sell | $0.60 | 10,203 | $6,111.60 | 120,594 | |
| Ogden Christopher | CTMX | Chief Financial Officer | Mar 18 '25 | Sell | $0.60 | 8,551 | $5,122.05 | 201,026 | |
| BELVIN MARCIA | CTMX | SVP, Chief Scientific Officer | Mar 18 '25 | Sell | $0.60 | 19,512 | $11,687.69 | 248,636 |
Latest CytomX Therapeutics Inc. News
CTMX Breaking Stock News: Dive into CTMX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
Zacks
5 days ago
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
Zacks
5 days ago
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Zacks
6 days ago
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
Zacks
9 days ago
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Zacks
9 days ago
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
Zacks
17 days ago
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
Zacks
19 days ago
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
Compare CTMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTMX CytomX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.